Podcasts about eml4 alk

  • 7PODCASTS
  • 10EPISODES
  • 21mAVG DURATION
  • ?INFREQUENT EPISODES
  • Sep 19, 2023LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about eml4 alk

Latest podcast episodes about eml4 alk

いんよう!
第266回【個人的に伏線回収した論文】

いんよう!

Play Episode Listen Later Sep 19, 2023 41:11


今年のノーベル賞は、あの時たまたま読んだ論文のやつか!みたいな話をしています。 【回収した論文たち】 iPS論文 Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors ALK発癌の論文 Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Autophagy論文 The role of autophagy during the early neonatal starvation period 相分離の論文 Phase separation drives heterochromatin domain formation いんよう!YouTubeチャンネル いんよう!Twitter いんよう!ブログ いんよう!文字起こし アーカイブ by Keiさん(本編の音声の文字起こしをnoteに上げてくれています)

phase kei eml4 alk
Oncotarget
Aggressive Luminal Breast Cancer: Are Cis-Spliced Fusion Proteins Pathological?

Oncotarget

Play Episode Listen Later Aug 22, 2023 3:29


A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “Are cis-spliced fusion proteins pathological in more aggressive luminal breast cancer?” A vast majority of breast cancers (~70%) are estrogen receptor-alpha positive (ER+), for which endocrine therapy is the common treatment. However, recurrence often occurs leading to tumor progression, metastasis and eventually patient death, and the underlying molecular mechanisms remain poorly understood. In this new editorial, researchers Chia-Chia Liu and Xiao-Song Wang from the University of Pittsburgh discuss their recent study regarding recurrent gene fusions — hallmarks of some cancers that resulted either from chromosomal rearrangements or from cis- or trans-splicing. “Importantly, selected oncogenic fusions have been matched with effective targeted therapy in several solid tumors. For instance, EML4-ALK, one of the most important oncogenic driver genes of non-small cell lung cancer (NSCLC) uncovered in recent years.” In addition to gene fusions resulting from genomic rearrangements, a read-through SLC45A3-ELK4 fusion transcript has been identified in prostate cancer which is associated with disease progression and metastasis. Although the whole genome and RNA sequencing provide an effective way to detect fusion genes, the downstream identification and validation of fusion genes or their products in solid tumors remains a major challenge. Through analysis of RNA-seq data from TCGA, the authors of this editorial and their co-authors recently identified a neoplastic fusion transcript RAD51AP1-DYRK4 in luminal B breast cancer (~17.5%) showing higher ki67 expression which is an indication of aggressive clinical characteristics. “In this study, we examined the utility of MEK inhibitor trametinib (Mekinist) currently used for treating melanoma with BRAF mutations, in blocking the MEK-ERK signaling driven by RAD51AP1-DYRK4 fusion. Interestingly [...] RAD51AP1-DYRK4 may endow sensitivity to MEK inhibition in luminal B breast cancer [13]. To our knowledge, this is one of the few non-traditional fusions generated by read-through events in the absence of DNA rearrangement that play an important role in tumorigenesis.” DOI - https://doi.org/10.18632/oncotarget.28438 Correspondence to - Xiao-Song Wang - xiaosongw@pitt.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28438 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, luminal B breast cancer, RAD51AP1-DYRK4, MEK inhibitor, chimerical transcript About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Oncotarget
Table of Contents: Volume 12, Issue #19

Oncotarget

Play Episode Listen Later Sep 15, 2021 11:00


Listen to summaries of the latest oncology-focused research published in this week's issue of Oncotarget, Volume 12, Issue 19. https://www.oncotarget.com/archive/v12/i19/ Cover Paper - “Nanoparticle T cell engagers for the treatment of acute myeloid leukemia” https://doi.org/10.18632/oncotarget.28054 News - “Old drug, new trick: proton pump inhibitors find new purpose in cancer care” https://doi.org/10.18632/oncotarget.28053 (PDF Download) Research Paper - “Novel insights into the molecular mechanisms underlying risk of colorectal cancer from smoking and red/processed meat carcinogens by modeling exposure in normal colon organoids” https://doi.org/10.18632/oncotarget.28058 Research Paper - “Altered glucuronidation deregulates androgen dependent response profiles and signifies castration resistance in prostate cancer” https://doi.org/10.18632/oncotarget.28059 Research Paper - “The antitumoral effects of chemerin are independent from leukocyte recruitment and mediated by inhibition of neoangiogenesis” https://doi.org/10.18632/oncotarget.28056 Research Paper - “Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer” https://doi.org/10.18632/oncotarget.28068 Research Paper - “High expression of Myosin 1g in pediatric acute lymphoblastic leukemia” https://doi.org/10.18632/oncotarget.28055 Case Report - “Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition” https://doi.org/10.18632/oncotarget.28062 Research Perspective - “Towards precision oncology in angiosarcomas using next generation “omic” technologies” https://doi.org/10.18632/oncotarget.27996 Research Perspective - “Targeting AP-1 transcription factors by CRISPR in the prostate” https://doi.org/10.18632/oncotarget.27997 Research Perspective - “The role of dynamic phenotypes in cancer” https://doi.org/10.18632/oncotarget.28006 Keywords - colon organoids, acute myeloid leukemia, prostate cancer, chemerin, KIF11 inhibition, breast cancer, acute lymphoblastic leukemia, ALK inhibitors, rare cancer, dynamic phenotype, Lung cancer, cancer, science, research, oncology About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/oncotargetyoutube Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

AACR 2015
'Liquid biopsy' may help earlier detection of lung cancer treatment resistance

AACR 2015

Play Episode Listen Later Oct 31, 2015 3:43


Dr Nilsson talks to ecancertv at AACR 2015 about the development of a blood test which regularly monitors for the presence of the rearrangement of the EML4-ALK gene fusion in patients with non-small cell lung cancer (NSCLC), helping clinicians predict the outcome of treatment with crizotinib.

This Week in Pediatric Oncology
TWiPO #19 ~ More on Hedgehog signaling, brain tumor risk from cell phone use, and FDA approval of cancer drugs

This Week in Pediatric Oncology

Play Episode Listen Later Feb 10, 2014 33:22


October 30, 2011Several just-published papers in the literature relate to recent podcast episodes, and host Dr. Tim Cripe and co-host Dr.  Lionel Chow review these interesting developments. 0:55 Hedgehog Signaling: Recent papers discussing this pathway in neuroblastoma and rhabdomyosarcoma are discussed, with implications for treatment in these tumor types with itraconozole. 6:40 Cell phone and brain tumor risk: The controversy concerning criticism by the Environmental Health Trust of a study showing that cell phone use does not increase risk of brain tumors in children is explored. Accelerated approval of cancer drugs by the FDA and implications for pediatric cancers. 15:30 Brentuximab for two types of lymphoma 21:20 Vemurafenib for melanoma 28:30 Crizotinib for non-small cell lung cancer (and potential use in neuroblastoma) 42:30 Response to email regarding personalized medicine TWiPO episode #17 and lab blog for Dr Charles Keller at OHSU References: Pediatr Blood Cancer. 2011 Dec 1;57(6):930-8. doi: 10.1002/pbc.23174. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group. Int J Oncol. 2011 Oct;39(4):899-906. doi: 10.3892/ijo.2011.1076. Pharmacological inhibition of the Hedgehog pathway preventshuman rhabdomyosarcoma cell growth. Cancer Lett. 2011 Nov 28;310(2):222-31. Inhibition of the sonic hedgehog pathway by cyplopaminereduces the CD133+/CD15+ cell compartment and the in vitrotumorigenic capability of neuroblastoma cells. Cell Phone Study Was Flawed, Say Some Experts by Roxanne Nelson Medscape Oncology News. The JNCI Study by Aydin et al on Risk of Childhood Brain Cancer from Cellphone Use Reveals Serious Health Problems, Environmental Health Trust. N Engl J Med. 2010 Nov 4;363(19):1812-21. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. FDA Approves Brentuximab for Two Lymphomas By: ELIZABETH MECHCATIE, Oncology Report Digital Network. Clin Cancer Res. 2011 Oct 15;17(20):6428-36. Brentuximab Vedotin (SGN-35). FDA Approves Vemurafenib for Advanced Melanoma. By: JANE SALODOF MACNEIL, Oncology Report Digital Network. N Engl J Med. 2011 Jun 30;364(26):2507-16. Improved survival with vemurafenib in melanoma with BRAFV600E mutation. N Engl J Med. 2011 Jun 30;364(26):2547-8. Been there, not done that--melanoma in the age of molecular therapy. http://www.ncbi.nlm.nih.gov/pubmed/21639809 Biochem J. 2011 Aug 15. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. N Engl J Med. 2010 Oct 28;363(18):1693-703. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. Nature. 2007 Aug 2;448(7153):561-6. Epub 2007 Jul 11. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Science. 1994 Mar 4;263(5151):1281-4. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

18e CPLF Marseille 2014
Quelle stratégie thérapeutique en cas de réarrangement EML4-ALK ?

18e CPLF Marseille 2014

Play Episode Listen Later Feb 2, 2014 25:14


Quelle stratégie thérapeutique en cas de réarrangement EML4-ALK ?

GRACEcast Lung Cancer Audio
Q and A Session on The Emerging Role of Molecular Markers in NSCLC: a Webinar by Dr. Nathan Pennell (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Mar 7, 2010 14:45


Q&A Session following webinar with Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, on the use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.

GRACEcast Lung Cancer Video
Q and A Session on The Emerging Role of Molecular Markers in NSCLC: a Webinar by Dr. Nathan Pennell (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Mar 7, 2010 14:44


Q&A Session following webinar with Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, on the use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.

GRACEcast Lung Cancer Audio
The Emerging Role of Molecular Markers in Non-Small Cell Lung Cancer: a Webinar by Dr. Nathan Pennell (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Jan 30, 2010 35:03


Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, reviews the current evidence and future directions for use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.    

GRACEcast Lung Cancer Video
The Emerging Role of Molecular Markers in Non-Small Cell Lung Cancer: a Webinar by Dr. Nathan Pennell (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Jan 30, 2010 35:01


Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, reviews the current evidence and future directions for use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.